I sent a series of questions to IR, and recieved a pretty prompt reply from Chris.  Not a lot of information given out, but one thing he did mention is that, "our partnership with Eversana remains in place. As mentioned in our recent MD&A, Resverlogix and EVERSANA have mutually agreed to temporarily pause services until additional capital is raised, but we are looking forward to resuming our work together as soon as financing is secured."

Forgive me if I'm late to the game here, but did any of our sharps on the board pick this up from the MD&A? A pause with Eversana? At least the bills aren't racking up while we're stuck, one would hope.

Another part of the response echoed what others have recieved recently:

"I do not have a firm timeline for you as to when we will provide our next updates to shareholders. As our management team has previously announced, we are currently pursuing three main goals: 1. Financing, 2. Clinical development of apabetalone, and 3. Partnerships. All of these endeavors take time to accomplish and require confidential negotiation with external parties (eg. regulators and potential partners). Even though it has been a quiet period in terms of news, I can assure you we are working hard to accomplish our stated goals and deliver value for shareholders."

Here's to hoping those confidential negotiations produce an enormous sum of money: either in the form of financing for the type of trial that will actually put this drug in the pharmacies, or a tidy sum to put the whole company in the portfolio of a BP better positioned to advance the technology.  I can't see how this can possibly drag on much longer without one of the two.  For some reason (call it optimism?) I don't see this company folding, so I think it's one of the two piles of cash coming through the doors. Sometimes (foolish?) patience is rewarded, right?